Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Starling Oncology Inc
STLN
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$3.58
0.04
1.13%
Ult. Agg.: Nov 17, 9:28 AM
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Starling Oncology Financials
Starling Oncology (STLN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Starling Oncology Narrows FY2026 Sales Guidance from $650.000M-$670.000M to $650.000M-$660.000M vs $663.685M Est
Starling Oncology (NASDAQ:STLN) narrows FY2026 sales outlook from $650.000 million-$670.000 million to $650.000 million-$660.000 million vs $663.685 million estimate.
Benzinga Newsdesk
PRO
Starling Oncology Q3 EPS $(0.13) Misses $(0.05) Estimate, Sales $169.767M Beat $169.047M Estimate
Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 7.14 percent increase over losses of $(0.14) per share from
Benzinga Newsdesk
PRO
Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY
Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.08) per share. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $161.282 million in
Benzinga Newsdesk